Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors.
Fiche du document
17 janvier 2023
- doi: 10.1016/j.xcrm.2022.100900
- issn: 2666-3791
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.xcrm.2022.100900
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/36652909
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2666-3791
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_B718E4D7ABEC8
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Citer ce document
Á.F. Álvarez-Prado et al., « Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors. », Serveur académique Lausannois, ID : 10.1016/j.xcrm.2022.100900
Métriques
Partage / Export
Résumé
Brain metastases (BrMs) are the most common form of brain tumors in adults and frequently originate from lung and breast primary cancers. BrMs are associated with high mortality, emphasizing the need for more effective therapies. Genetic profiling of primary tumors is increasingly used as part of the effort to guide targeted therapies against BrMs, and immune-based strategies for the treatment of metastatic cancer are gaining momentum. However, the tumor immune microenvironment (TIME) of BrM is extremely heterogeneous, and whether specific genetic profiles are associated with distinct immune states remains unknown. Here, we perform an extensive characterization of the immunogenomic landscape of human BrMs by combining whole-exome/whole-genome sequencing, RNA sequencing of immune cell populations, flow cytometry, immunofluorescence staining, and tissue imaging analyses. This revealed unique TIME phenotypes in genetically distinct lung- and breast-BrMs, thereby enabling the development of personalized immunotherapies tailored by the genetic makeup of the tumors.